<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37881130</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial.</ArticleTitle><Pagination><StartPage>2262635</StartPage><MedlinePgn>2262635</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2262635</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2023.2262635</ELocationID><Abstract><AbstractText>This was a phase 1 dose-escalation study of ZR202-CoV, a recombinant protein vaccine candidate containing a pre-fusion format of the spike (S)-protein (S-trimer) combined with the dual-adjuvant system of Alum/CpG. A total of 230 participants were screened and 72 healthy adults aged 18-59 years were enrolled and randomized to receive two doses at a 28-day interval of three different ZR202-CoV formulations or normal saline. We assessed the safety for 28 days after each vaccination and collected blood samples for immunogenicity evaluation. All formulations of ZR202-CoV were well-tolerated, with no observed solicited adverse events ≥ Grade 3 within 7 days after vaccination. No unsolicited adverse events ≥ Grade 3, or serious adverse events related to vaccination occurred as determined by the investigator. After the first dose, detectable immune responses were observed in all subjects. All subjects that received ZR202-CoV seroconverted at 14 days after the second dose by S-binding IgG antibody, pseudovirus and live-virus based neutralizing antibody assays. S-binding response (GMCs: 2708.7 ~ 4050.0 BAU/mL) and neutralizing activity by pseudovirus (GMCs: 363.1 ~ 627.0 IU/mL) and live virus SARS-CoV-2 (GMT: 101.7 ~ 175.0) peaked at 14 days after the second dose of ZR202-CoV. The magnitudes of immune responses compared favorably with COVID-19 vaccines with reported protective efficacy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Guang-Wei</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>Vaccine Clinical Research Center, Henan Provincial Center for Disease Control and Prevention, Zhenzhou, HA, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhong-Fang</ForeName><Initials>ZF</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease &amp; National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, GD, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Drug and Vaccine Research, Guangzhou Laboratory, Bioland, Guangzhou, GD, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Hepatitis and Enterovirus Vaccine, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lan</LastName><ForeName>Qin-Ying</ForeName><Initials>QY</Initials><AffiliationInfo><Affiliation>R&amp;D Department, Shanghai Zerun Biotechnology Co. Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ni</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Medicine, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Ya-Zheng</ForeName><Initials>YZ</Initials><AffiliationInfo><Affiliation>School of Medicine, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chen-Fei</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Department of Hepatitis and Enterovirus Vaccine, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Ting-Ting</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease &amp; National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, GD, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Li-Li</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Vaccine Clinical Research Center, Henan Provincial Center for Disease Control and Prevention, Zhenzhou, HA, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Yong-Qiang</ForeName><Initials>YQ</Initials><AffiliationInfo><Affiliation>Vaccine Program Office, Xiangcheng County Center for Disease Control and Prevention, Xiangcheng, HA, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Zhi-Wei</ForeName><Initials>ZW</Initials><AffiliationInfo><Affiliation>Statistics and Decision Sicence, Beijing Key Tech Statistical Consulting Co. Ltd, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>R&amp;D Department, Shanghai Zerun Biotechnology Co. Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Bang-Wei</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>R&amp;D Department, Shanghai Zerun Biotechnology Co. Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Xi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>R&amp;D Department, Shanghai Zerun Biotechnology Co. Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jing-Jing</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>R&amp;D Department, Walvax Biotechnology Co. Ltd, Kunming, Yunnan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Shu-Yuan</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>R&amp;D Department, Walvax Biotechnology Co. Ltd, Kunming, Yunnan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>R&amp;D Department, Walvax Biotechnology Co. Ltd, Kunming, Yunnan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Ling-Yun</ForeName><Initials>LY</Initials><AffiliationInfo><Affiliation>R&amp;D Department, Shanghai Zerun Biotechnology Co. Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ge</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>R&amp;D Department, Shanghai Zerun Biotechnology Co. Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>R&amp;D Department, Shanghai Zerun Biotechnology Co. Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>R&amp;D Department, Walvax Biotechnology Co. Ltd, Kunming, Yunnan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jin-Cun</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Respiratory Disease &amp; National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, GD, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Drug and Vaccine Research, Guangzhou Laboratory, Bioland, Guangzhou, GD, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Zhong-Yu</ForeName><Initials>ZY</Initials><AffiliationInfo><Affiliation>Department of Hepatitis and Enterovirus Vaccine, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Zhi-Qiang</ForeName><Initials>ZQ</Initials><AffiliationInfo><Affiliation>Vaccine Clinical Research Center, Henan Provincial Center for Disease Control and Prevention, Zhenzhou, HA, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>34S289N54E</RegistryNumber><NameOfSubstance UI="C041524">aluminum sulfate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000723087">ZR202-CoV COVID-19 vaccine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 vaccine</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">placebo-controlled</Keyword><Keyword MajorTopicYN="N">recombinant protein vaccine</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList><CoiStatement>The authors declare the following competing interests: Q-Y Lan, Q Yang, B-W Yu, X Han, L-Y Zhou, G Liu and K Li are full-time employees of the manufacturer. Other authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>26</Day><Hour>3</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37881130</ArticleId><ArticleId IdType="pmc">PMC10644802</ArticleId><ArticleId IdType="doi">10.1080/21645515.2023.2262635</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang P, Liu T, Huang L, Liu H, Lei M, Xu W, Hu X, Chen J, Liu B.. Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion. Radiology. 2020;295(1):22–8. doi:10.1148/radiol.2020200330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2020200330</ArticleId><ArticleId IdType="pmc">PMC7233360</ArticleId><ArticleId IdType="pubmed">32049600</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO validates 11th vaccine for COVID-19. 2022.</Citation></Reference><Reference><Citation>Poland GA, Ovsyannikova IG, Crooke SN, Kennedy RB. SARS-CoV-2 vaccine development: current status. Mayo Clin Proc. 2020;95(10):2172–88. doi:10.1016/j.mayocp.2020.07.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2020.07.021</ArticleId><ArticleId IdType="pmc">PMC7392072</ArticleId><ArticleId IdType="pubmed">33012348</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav T, Srivastava N, Mishra G, Dhama K, Kumar S, Puri B, Saxena SK. Recombinant vaccines for COVID-19. Hum Vaccin Immunother. 2020;16(12):2905–12. doi:10.1080/21645515.2020.1820808.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1820808</ArticleId><ArticleId IdType="pmc">PMC7711739</ArticleId><ArticleId IdType="pubmed">33232211</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Zhou C, An J, Song Y, Yu P, Li J, Gu C, Hu D, Jiang Y, Zhang L, et al. Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and Alum/CpG adjuvants. Vaccine. 2021;39(48):7001–11. doi:10.1016/j.vaccine.2021.10.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.10.066</ArticleId><ArticleId IdType="pmc">PMC8556577</ArticleId><ArticleId IdType="pubmed">34750014</ArticleId></ArticleIdList></Reference><Reference><Citation>GSK . Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine; [accessed 2022 Aug
29]. https://www.gsk.com/en-gb/media/press-releases/sanofi-gsk-first-to-report.</Citation></Reference><Reference><Citation>CLOVER . Clover’s COVID-19 vaccine candidate demonstrates strong cross-neutralization against Omicron as a homologous booster; [accessed 2022 Aug
29]. https://ir.cloverbiopharma.com/zh-hant/news-releases/news-release-details-24.</Citation></Reference><Reference><Citation>CLOVER . Clover announces positive phase 2/3 results in adolescents for its COVID-19 vaccine; [accessed 2022 Aug
29]. https://ir.cloverbiopharma.com/zh-hant/news-releases/news-release-details-25.</Citation></Reference><Reference><Citation>National Medical Products Administration . Guidelines for adverse event classification standards for clinical trials of preventive vaccines. 2019.</Citation></Reference><Reference><Citation>Richmond P, Hatchuel L, Dong M, Ma B, Hu B, Smolenov I, Li P, Liang P, Han HH, Liang J, et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10275):682–94. doi:10.1016/S0140-6736(21)00241-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00241-5</ArticleId><ArticleId IdType="pmc">PMC7906655</ArticleId><ArticleId IdType="pubmed">33524311</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosino D, Han HH, Hu B, Liang J, Clemens R, Johnson M, Siber G, Goldblatt D. Immunogenicity of SCB-2019 coronavirus Disease 2019 vaccine compared with 4 approved vaccines. J Infect Dis. 2022;225(2):327–31. doi:10.1093/infdis/jiab574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab574</ArticleId><ArticleId IdType="pmc">PMC8763959</ArticleId><ArticleId IdType="pubmed">34888662</ArticleId></ArticleIdList></Reference><Reference><Citation>Bravo L, Smolenov I, Han HH, Li P, Hosain R, Rockhold F, Clemens SAC, Roa C, Borja-Tabora C, Quinsaat A, et al. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2022;399(10323):461–72. doi:10.1016/S0140-6736(22)00055-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00055-1</ArticleId><ArticleId IdType="pmc">PMC8776284</ArticleId><ArticleId IdType="pubmed">35065705</ArticleId></ArticleIdList></Reference><Reference><Citation>Barry M, Cooper C. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. Exp Opin Biol Ther. 2007;11:1731–7. doi:10.1517/14712598.7.11.1731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.7.11.1731</ArticleId><ArticleId IdType="pubmed">17961095</ArticleId></ArticleIdList></Reference><Reference><Citation>Moderbacher CR, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, Belanger S, Abbott RK, Kim C, Choi J, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183:996–1012.e19. doi:10.1016/j.cell.2020.09.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.038</ArticleId><ArticleId IdType="pmc">PMC7494270</ArticleId><ArticleId IdType="pubmed">33010815</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11. doi:10.1038/s41591-021-01377-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimeglio C, Herin F, Martin-Blondel G, Miedougé M, Izopet J. Antibody titers and protection against a SARS-CoV-2 infection. J Infect. 2022;84(2):248–88. doi:10.1016/j.jinf.2021.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.09.013</ArticleId><ArticleId IdType="pmc">PMC8452591</ArticleId><ArticleId IdType="pubmed">34560135</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh SM, Liu WD, Huang YS, Lin YJ, Hsieh EF, Lian WC, Chen C, Janssen R, Shih S-R, Huang C-G, et al. Safety and immunogenicity of a recombinant stabilized prefusion SARS-CoV-2 spike protein vaccine (MVC-COV1901) adjuvanted with CpG 1018 and aluminum hydroxide in healthy adults: a phase 1, dose-escalation study. EClinicalMedicine. 2021;38:100989. doi:10.1016/j.eclinm.2021.100989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.100989</ArticleId><ArticleId IdType="pmc">PMC8233066</ArticleId><ArticleId IdType="pubmed">34222848</ArticleId></ArticleIdList></Reference><Reference><Citation>Naranbhai V, Garcia-Beltran WF, Chang CC, Berrios Mairena C, Thierauf JC, Kirkpatrick G, Onozato ML, Cheng J, St Denis KJ, Lam EC, et al. Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 vaccines. J Infect Dis. 2022;225(7):1141–50. doi:10.1093/infdis/jiab593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab593</ArticleId><ArticleId IdType="pmc">PMC8689763</ArticleId><ArticleId IdType="pubmed">34888672</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenck RW Jr., Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, Perez JL, Walter EB, Senders S, Bailey R, et al. Safety, immunogenicity, and efficacy of the BNT162b2 covid-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239–50. doi:10.1056/NEJMoa2107456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107456</ArticleId><ArticleId IdType="pmc">PMC8174030</ArticleId><ArticleId IdType="pubmed">34043894</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Ma X, Yan G, Wu Y, Chen Y, Zhou Z, Wan N, Su W, Liu F-W, Dai M-X, et al. Precise-CoVaccine study group. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: a randomised, double-blinded, placebo-controlled, phase 2 trial. EClinicalMedicine. 2022;54:101680. doi:10.1016/j.eclinm.2022.101680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101680</ArticleId><ArticleId IdType="pmc">PMC9517939</ArticleId><ArticleId IdType="pubmed">36188435</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Luo MT, Wu Q, Wang YX, Ma X, Yan G, Zhang S-H, Chen Y, Wan N, Zhang L, et al. Precise-CoVaccine study group. Long-term and effective neutralization against omicron sublineages elicited by four platform COVID-19 vaccines as a booster dose. Cell Discov. 2023;9(1):17. doi:10.1038/s41421-023-00518-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-023-00518-2</ArticleId><ArticleId IdType="pmc">PMC9907876</ArticleId><ArticleId IdType="pubmed">36754955</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, An J, Liu K, Yu P, Fang X, Li J, Zhu H, Zhu Q, Huang C, Zhang C, et al. A potent, broadly protective vaccine against SARS-CoV-2 variants of concern. NPJ Vaccines. 2022;7(1):144. doi:10.1038/s41541-022-00571-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-022-00571-0</ArticleId><ArticleId IdType="pmc">PMC9653380</ArticleId><ArticleId IdType="pubmed">36371432</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>